Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.
- Revenue in HKD (TTM)1.50bn
- Net income in HKD-236.58m
- Incorporated2015
- Employees1.18k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609913
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
Mergers & acquisitions
| Acquired company | 688428:SHH since announced | Transaction value |
|---|---|---|
| Guangzhou Innocare Pharma Tech Co Ltd | -23.92% | 65.07m |
| Holder | Shares | % Held |
|---|---|---|
| HHLR Advisors Ltd.as of 14 Jan 2025 | 280.62m | 18.76% |
| Aegon-Industrial Fund Management Co., Ltd.as of 05 Aug 2025 | 74.67m | 4.99% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 46.25m | 3.09% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 31.57m | 2.11% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 22.75m | 1.52% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 22.29m | 1.49% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 17.17m | 1.15% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 11.38m | 0.76% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 10.10m | 0.68% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 9.77m | 0.65% |
